Administration of PPARγ agonists (as therapeutic treatment in bronchopulmonary dysplasia) inhibits the canonical WNT/TGF-β pathway and stimulates PPARγ activity [72]. The gene discussed is PPARG; the disease is bronchopulmonary dysplasia.